misleading statements

Securities class action filed against $RARE for allegedly misrepresenting setrusumab efficacy data. Investors may claim damages; lead plaintiff deadline April 6, 2026.

Rosen Law Firm files securities class action against Inovio Pharmaceuticals ($INO) alleging misleading statements on manufacturing deficiencies and overstated regulatory prospects. Lead plaintiff deadline April 7, 2026.

Hagens Berman investigates $BRBR for securities fraud, alleging inflated 2025 sales were driven by retailer inventory hoarding, not consumer demand. Stock crashed 33% after destocking.

Rosen Law Firm urges PomDoctor Ltd. investors to join securities class action before April 7, 2026 deadline. Allegations include false statements, insider dumping, and artificial trading schemes.

Class action lawsuit filed against $PLUG alleging false statements about DOE funding and hydrogen facilities between January-November 2025. Investors have until April 3, 2026 to join.

Rosen Law Firm alerts $METC investors of securities class action lawsuit alleging false statements about mining operations. Class certification deadline set for March 31, 2026.

Snowflake faces securities class action alleging failure to disclose how product efficiency improvements would materially harm consumption-based revenue model.

Securities lawsuit alleges $BBWI made false statements about business strategy and financial guidance. Investors have until March 16, 2026 deadline to join litigation.

Securities class action filed against VTGN alleges misleading statements about fasedienol drug and PALISADE-3 trial. Investors must act by March 16, 2026 deadline.

Rosen Law Firm alerts investors in multiple securities litigation cases, including $PMI, urging them to secure counsel before critical claim deadlines.

Class action lawsuit filed against $CWH over false inventory and demand statements. Stock fell 25% post-Q3, another 16% after Q4 results revealed inventory corrections and dividend suspension.

Grabar Law Office investigates securities fraud claims against $ASPI, $CWH, $EOSE, and $SLNO for alleged disclosure failures. Long-term shareholders may seek compensation and reforms at no cost.

Robbins Geller launches class action lawsuit against $SNOW, alleging securities fraud over false product efficiency claims and material business disclosures between June 2023 and February 2024.

Securities lawsuit filed against $RGNX for allegedly misleading investors about RGX-111 gene therapy efficacy and safety. Lead plaintiff deadline April 14, 2026.

Aquestive Therapeutics faces securities class action over alleged false FDA approval statements for Anaphylm drug. Stock fell 37% after January 2026 NDA rejection.

Securities class action filed against $RARE over alleged misstatements about setrusumab drug efficacy. Failed clinical trials triggered 25-42% stock declines. Investor deadline: April 6, 2026.

Class action lawsuit filed against $NAAM alleges October 2025 IPO prospectus contained false statements about sales and marketing expenses. Lead plaintiff deadline: April 24, 2026.

Rosen Law Firm pursues class action against Eos Energy Enterprises for alleged false statements about operations and guidance. Investors must act by May 5, 2026 deadline.

ODDITY Tech faces class action lawsuit alleging concealment of ad partner algorithm changes that inflated customer acquisition costs. Stock fell 49% after CEO disclosure on February 25.

Rosen Law Firm files securities class actions against Nektar Therapeutics, Enphase Energy, and Aquestive Therapeutics. Investors have until May 5, 2026 to join.